BHVN · Biohaven

The thesis

Biohaven Ltd. is modestly more likely than not to beat the S&P 500 over the next three months. The US antitrust waiting period on its SK Biopharmaceuticals licence expired on 28 October 2026, so the $350 million closing payment now rests on routine conditions, and the RISE3 epilepsy topline result, guided for the second half of 2026, settles the case.

The shares closed at $15.19 on 11 November 2026, 2.3% above the 3-month reference close of $14.85 on 13 August 2026. That is 16.7% below the 52-week intraday high of $18.24 set on 26 August 2026, the day the SK licence was announced. The market has priced in a likely SK closing and a fair chance of a positive RISE3 result, but not the high of the licence announcement. No announcement that the SK payment has been received had appeared in company news by 11 November 2026.

Bullish and bearish views on Biohaven Ltd.

The bull case on Biohaven Ltd. (BHVN), in brief: the SK closing hurdle has cleared. The bear case: the regulatory hold on opakalim remains.

Bull case

• The SK closing hurdle has cleared. Biohaven's third-quarter release (29 October 2026) says the Hart-Scott-Rodino waiting period expired on 28 October 2026. The licence pays $350 million at closing and $50 million one year later (Form 8-K, 26 August 2026).
• Ono cash has arrived. The same release says the $80 million upfront payment from Ono Pharmaceutical was received on 20 October 2026. A $20 million milestone is expected within a year, along with royalties of about 20% on Ono's net sales in Japan, South Korea, Taiwan and the ASEAN countries.
• The epilepsy study is fully enrolled. RISE3 dosing of more than 600 randomized patients continues, and topline results remain guided for the second half of 2026 (Q3 release, 29 October 2026).
• A second regulatory path is open. The FDA accepted the Vyglxia (troriluzole) resubmission for spinocerebellar ataxia as a complete response to the 4 November 2025 action letter. The user-fee goal date falls in the first quarter of 2027, and an advisory committee meeting is planned (Q3 release, 29 October 2026).
• Pipeline work continues beyond epilepsy. Biohaven announced on 5 November 2026 active enrollment in the pivotal Phase 3 trial of BHV-1300 in Graves' disease, plus three scientific presentations.
• Analyst targets sit well above the share price. Canaccord Genuity kept Buy and raised its target to $32 (31 October 2026). Morgan Stanley kept Overweight and raised its target to $21 (3 November 2026). Deutsche Bank kept Buy with a $23 target, down from $26 (30 October 2026).

Bear case

• The regulatory hold on opakalim remains. The FDA partial clinical hold dated 4 September 2026 pauses new enrolment, after rodent metabolite findings. RISE2 enrolment stays paused pending nonclinical data the company expects "in the coming weeks" (Q3 release, 29 October 2026).
• Cash is thin without the SK payment. Cash, equivalents, marketable securities and restricted cash were about $164.0 million at 30 September 2026, against about $270.5 million at 30 June 2026. The third-quarter net loss was $129.3 million, or $0.86 per share, and the nine-month loss was $397.1 million (Q3 release).
• The readout is a single event. RISE3 must separate from placebo on its primary endpoint. A miss would weaken the lead asset the SK licence is built around, and the outcome is not known in advance.
• The shares are volatile around news. They closed at $15.24 on 4 November 2026, fell to $13.90 on 5 November 2026 and recovered to $15.23 by 9 November 2026 (daily closes).
• The 52-week high has not been retaken. The shares have stayed below the $18.24 intraday high of 26 August 2026 for more than two months, so the licence announcement's gain was

Price setup

The shares closed at $15.19 on 11 November 2026. They sit above the 50-day average of $13.59 and the 200-day average of $12.31 (adjusted daily closes, as of 11 November 2026). The 52-week closing low was $7.95 on 12 November 2025, so the shares have nearly doubled from that low.

The 52-week intraday high of $18.24 (26 August 2026) is the level that marks a full recovery of the licence-announcement move. The 50-day average is the nearest support on the closing series, about 10% below the last close.

The range since 4 November 2026 has been tight, from a $13.90 close to $15.24. The next large move depends on the SK closing announcement and the RISE3 result. Neither has a confirmed date.

Catalysts ahead

• ~15 November 2026 (est.): Announcement that the SK Biopharmaceuticals licence has closed and the $350 million is received. Confirms the funding premise after the antitrust waiting period expired on 28 October 2026; no receipt had been announced by 11 November 2026.
• 19 November 2026: BHV-1530 oral presentation at ENA 2026 (EORTC-NCI-AACR), Barcelona. Tests whether early partial responses extend to a larger Phase 1 dataset.
• ~30 November 2026 (est.): Nonclinical data on the opakalim rodent metabolite, guided for 'the coming weeks'. Determines whether RISE2 enrolment can resume and whether the partial clinical hold narrows.
• ~31 December 2026 (est.): RISE3 topline results, guided for second half 2026. Decides whether the lead epilepsy drug separates from placebo on its primary endpoint.
• ~31 March 2027 (est.): FDA user-fee goal date for the Vyglxia (troriluzole) resubmission, first quarter 2027. Sets the timing of a possible first approved product for spinocerebellar ataxia.

What would change the view

A daily close below $11.75, which would erase the gain made since before the SK licence's antitrust waiting period expired. A Biohaven filing disclosing termination or reduced terms of the SK licence, or an FDA hold extended to dosing of already-randomized patients, would also show the case failing.

The risks this note tracks, each with what would confirm it:

• The SK licence does not deliver its closing payment. Confirmed by: a Biohaven filing disclosing termination, reduced consideration or an unmet closing condition under the 26 August 2026 agreement.
• The opakalim safety restriction widens beyond new enrolment. Confirmed by: an FDA or Biohaven disclosure requiring dosing to halt for patients already randomized.
• RISE3 fails to separate from placebo on its primary endpoint. Confirmed by: topline RISE3 results, guided for second half 2026, showing a miss.
• Cash runs short if the SK payment is delayed. Confirmed by: a fourth-quarter cash balance well below the $164.0 million reported at 30 September 2026 without an SK receipt, or a new equity raise.

What it trades with

Biohaven trades on its own clinical events, chiefly the RISE3 readout and the SK closing, more than on sector moves. Small and mid-cap biotechnology shares move with funding conditions and the FDA's regulatory tone, which bears on the Vyglxia advisory committee and the first-quarter 2027 goal date. Other epilepsy and ion-channel developers can react to a RISE3 result, and SK Biopharmaceuticals' epilepsy franchise is tied to the same Kv7 platform.